SpanCHFIII: A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure

Sponsor

Tufts Medical Center (Other)

Overall Status

Completed

CT.gov ID

NCT02084992

Collaborator

Metro West Medical Center (Other)

212

Enrollment

Locations

Arms

Duration (Months)

106

Patients Per Site

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will randomize participants with a diagnosis of congestive heart failure and at least one risk factor for hospitalization to either a tablet computer and web based disease management program or a telephone based disease management program. Both interventions are home based with heart failure education and symptom monitoring provided by nurse managers. The nurse managers are in close communication with both the participants and the participants' physicians . The components of the disease management program have been developed at Tufts Medical Center and the New England Quality Care Alliance with studies showing improved clinical outcomes, including reduced hospitalizations. The goal of this study is to transition this successful home monitoring and disease management program to a tablet computer and web-based implementation to both improve clinical outcomes (reducing hospitalizations and improving self-perceived health status) and improve provider-patient satisfaction. We hypothesize that the tablet computer based disease management will decrease heart failure hospitalizations.

Condition or Disease	Intervention/Treatment	Phase
Congestive Heart Failure Diastolic Heart Failure Systolic Heart Failure	Other: Expanded technology disease management Other: Telephonic disease management	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

212 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multicenter Randomized Controlled Evaluation of Heart Failure Disease Management Using Advanced Telecommunications Within a Diverse Provider Network: The Specialized Primary and Networked Care in HF (SPAN-CHF) III Trial

Study Start Date :

Jun 1, 2014

Actual Primary Completion Date :

Sep 1, 2019

Actual Study Completion Date :

Sep 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Expanded technology disease management After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.	Other: Expanded technology disease management Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
Active Comparator: telephonic disease management After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.	Other: Telephonic disease management

Arm

Intervention/Treatment

Experimental: Expanded technology disease management

After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.

Other: Expanded technology disease management

Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.

Active Comparator: telephonic disease management

After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.

Other: Telephonic disease management

Outcome Measures

Primary Outcome Measures

Number of days hospitalized for heart failure per patient-year of follow-up [90 days]

Secondary Outcome Measures

All Cause Mortality [90 days]
Cardiovascular Mortality [90 days]
Number of days hospitalized for cardiovascular causes at 90 days [90 days]
Number of days hospitalized for any cause [90 days]
Change in health status as assessed by the SF-12 [90 days]
Change in self-care as assessed by the SCHFI [90 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients age ≥ 18 with a primary care provider or specialist that is participating within the Collaborative Health ACO.
Patient able to consent
A diagnosis of heart failure with at least one of the following risk factors:

Hospitalization for heart failure within the prior year
NYHA class III-IV symptoms
Most recent BNP ≥ 300 pg/mL (or Nt-proBNP ≥ 600 pg/mL) as long as within 90 days prior to enrollment

Exclusion Criteria:

Acute myocardial infarction, PCI or CABG within 30 days before enrollment
Planned revascularization procedures, cardiac mechanical support implantation, cardiac transplantation, or other cardiac surgery within 30 days following study randomization.
Illness other than heart failure deemed the principal limitation to life expectancy or principal cause of disability
Severe angina as the principal cause of limitation
Uncorrected valvular disease, except where valvular regurgitation was considered to be secondary to severe left ventricular dilation, or where surgical correction is deemed excessively risky or declined by the patient.
Moderate to severe dementia such that unable to participate in disease management program
Severe visual or auditory disability such that unable to participate in disease management program
Hospice care
Listed for heart transplantation
No access to a working telephone
Homeless or no stable home environment
Not speaking a language in which the educational documents have been translated